HLB Inc
KOSDAQ:028300
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31 700
120 800
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
HLB Inc
Cash & Cash Equivalents
HLB Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
HLB Inc
KOSDAQ:028300
|
Cash & Cash Equivalents
₩89.7B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
11%
|
CAGR 10-Years
45%
|
|
|
SD Biosensor Inc
KRX:137310
|
Cash & Cash Equivalents
₩482.4B
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Cash & Cash Equivalents
₩46B
|
CAGR 3-Years
42%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Cash & Cash Equivalents
₩19.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
H
|
Humasis Co Ltd
KOSDAQ:205470
|
Cash & Cash Equivalents
₩11.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
I
|
Interojo Co Ltd
KOSDAQ:119610
|
Cash & Cash Equivalents
₩10.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
HLB Inc
Glance View
HLB Inc. is a dynamic biopharmaceutical company dedicated to the discovery and development of innovative treatments for a range of serious diseases. Founded on the principles of scientific excellence and a commitment to patient care, HLB has quickly gained recognition for its robust portfolio of drug candidates targeting areas such as oncology, autoimmune diseases, and rare disorders. The company's strategic approach combines cutting-edge research with advanced clinical trials, leveraging partnerships with leading research institutions and healthcare organizations to propel its therapeutic innovations. With a strong financial backing and a clear vision for growth, HLB is not just about developing drugs; it’s about transforming patient outcomes and making a meaningful impact on global health. As an investor, HLB Inc. presents a compelling opportunity anchored in its core strengths: a seasoned management team with a proven track record, a rich pipeline of promising drug candidates, and a robust intellectual property portfolio that secures its market position. The company’s commitment to transparency and strategic operational decisions positions it well for sustainable growth in the competitive biopharmaceutical landscape. With the increasing demand for effective therapies and advancements in medical technology, HLB stands poised to unlock significant shareholder value while driving progress in medical treatment options. This compelling narrative of potential, combined with HLB's dedication to innovation, makes it an intriguing prospect for investors seeking exposure to the biopharmaceutical sector.
See Also
What is HLB Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
89.7B
KRW
Based on the financial report for Sep 30, 2024, HLB Inc's Cash & Cash Equivalents amounts to 89.7B KRW.
What is HLB Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
45%
Over the last year, the Cash & Cash Equivalents growth was -35%. The average annual Cash & Cash Equivalents growth rates for HLB Inc have been -20% over the past three years , 11% over the past five years , and 45% over the past ten years .
You don't have any saved screeners yet
